Home
About Us
In this Issue
Previous Issue
Editorial Board
How to Contribute
Advertise with Us
Editorial Calendar
Subcribe Now
Global Healthcare Releases provided by Business Wire

 The Publication & Databases on Biotechnology in the Asia Pacific
 
 More free   feature articles 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

INSIDE INDUSTRY
Joslin Diabetes Center Forms Alliance with Johnson & Johnson Innovation to Identify Exercise-Related Drug Targets to Improve Diabetes Management
Joslin Diabetes Center announces a research and development alliance with Johnson & Johnson Innovation and its affiliate Janssen Research & Development, LLC, to identify and advance early-stage, novel therapeutic projects for potential for commercialization and product development. The first joint project selected in the alliance will focus on identifying exercise-related drug targets for developing new diabetes treatments.

“Joslin is uniquely positioned to translate findings in the laboratory into new approaches for treatment of diabetes, and our alliance with Johnson & Johnson Innovation and Janssen Research & Development is an excellent example of how we can move our early discoveries to the clinic with our complementary capabilities,” said Dr. Nandan Padukone, Ph.D., MBA, VP of Commercialization and Ventures at Joslin. “We will continue to explore other technologies with Johnson & Johnson Innovation and mechanisms such as venture creation to advance them quickly towards drug development.”

The new alliance is based on pioneering studies by Joslin researchers showing that exercise can train multiple tissues in the body that in turn stimulate metabolic improvements in other tissues. “The concept of tissue-to-tissue communication has been around for a while, but more recently we have realized that ‘trained’ tissues may communicate to beneficially affect other tissues,” said Laurie Goodyear, Ph.D., Co-Head of the Integrative Physiology and Metabolism Section at Joslin and senior investigator on this research presented earlier this year at the American Diabetes Association’s 73rd annual Scientific Sessions. “Our efforts now are to derive specific factors that help this effect and explore the development into potential therapies for diabetes.”

Click here for the complete issue.


About Us | How to Contribute | How to Advertise With Us | Contact Us |

"The views expressed here does not necessarily reflect the views of Asia Pacific Biotech News or its staff."
Copyright © 2014 World Scientific Publishing Co. All rights reserved.